title: Comment on 'Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study'.
authors.affiliation: Department of Dermatology, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: S P
authors.initials: SP
authors.lastname: Menting
authors.forename: D V D
authors.initials: DV
authors.lastname: Kleij
authors.forename: T
authors.initials: T
authors.lastname: Rispens
authors.forename: P I
authors.initials: PI
authors.lastname: Spuls
authors.forename: L L A
authors.initials: LL
authors.lastname: Lecluse
mesh_terms: D000893:Anti-Inflammatory Agents / Q000097:blood*; D061067:Antibodies, Monoclonal, Humanized / Q000097:blood*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood* / Q000627:therapeutic use*; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood* / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor